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Abstract 
It is known that cells grown in 3D are more tolerant to drug treatment than those grown in dispersion but 
the mechanism for this is still not clear; cells grown in 3D have opportunities to develop inter-cell 
communication, but are also closely packed which may impede diffusion.  In this study we examine 
methods for dielectrophoresis-based cell aggregation of both suspension and adherent cell lines and 
compare the effect of various drugs on cells grown in 3D and 2D. Comparing viability of pharmacological 
interventions on 3D cell clusters against both suspension cells and adherent cells grown in monolayer, as 
well as against a unicellular organism with no propensity for intracellular communication, we suggest that 
3D aggregates of adherent cells, compared to suspension cells, show a substantially different drug 
response to cells grown in monolayer, which increases as the IC50 is approached. Further, a mathematical 
model of the system for each agent demonstrates that changes to drug response are due to inherent 
changes in the system of adherent cells from the 2D to 3D state. Finally, differences within 
electrophysiological membrane properties of the adherent cell type suggest this parameter plays an 
important role in the differences found in the 3D drug response.  
 
 
 
 
 
 
Introduction 
Whilst culture of adherent cells is most commonly performed by placing the cells in a flask and growing 
them in a monolayer, methods of producing three-dimensional (3D) cellular constructs have gained 
significant attention in recent years.  For example, evidence suggests that 3D structures can be a more 
accurate predictive model of drug response compared to conventional two-dimensional (2D) (monolayer) 
models. With 90% of promising preclinical drug treatments failing during human clinical trials, 3D models 
have emerged to bridge the gap between in vitro and in vivo cellular drug responses, whilst circumventing 
the numerous challenges in throughput associated with animal models 1-6.  In vitro models can provide 
the large sample sizes necessary for these preclinical tests, thus recent development has focused on 
creating 3D systems that adequately mimic living tissue to reduce the need for animal modelling.  3D 
models have demonstrated maintenance of natural cell shape, cell-cell and cell-extracellular matrix (ECM) 
interactions, as well as the effects of tissue architecture, all affect disease progression and drug responses 
in cells6-9. For example, disease progression and drug efficacy in cancer have been shown to vary 
significantly between 2D versus 3D constructs6-9.  There is also debate whether the mechanism 
underpinning this observed increase in drug resistance in 3D models is due to changes in the behaviour 
of cells due to cell-to-cell contact, the architecture contributing to varied cell-signalling or simply that the 
inner cells in a 3D construct are shielded from the drug due to the outer cells preventing diffusion of the 
drug across the whole cell mass, or drug diffusion parameters altering in the 3D models4-5.  
Early systems for 3D spheroid formation such as spinners, shakers, rotaries, and the hanging drop method 
are simple to use and are designed for mass fabrication. However, it is difficult to use these systems whilst 
maintaining a uniform size and geometry in micro-scale spheroids, which are crucial when investigating 
avascular effects in cell constructs9-15. Recent technologies have improved both the ease of use and 
geometrical consistency in these assays and have been used for many tissue engineering applications. 
Techniques include Perfecta3D and InSphero’s GravityPlus which have been utilised to investigate drug 
treatments on cancer as well as creating micro-tissues of liver, cardiac, and skin tissues16, as well as the 
AggreWell plate which has primarily been utilised to induce various cell differentiation from stem cells 
4,5,10, 16-19.  
In addition to these techniques, dielectrophoresis (DEP) has been employed as a method to construct cell 
clusters in polymer hydrogels.  DEP has been used for creating stem cell niches 20-21 and to assess drug 
efficacy22-24.DEP is the movement of polarisable particles in a non-uniform electric field25-27 and causes 
either attraction to (positive DEP) or repulsion from (negative DEP)  high electric field regions, such as 
electrode edges.   It can be used to position cells by directing cells to move to a place of aggregation, or 
as a tool for assessing their electrophysiology by measuring frequency-dependent behaviour. It provides 
an attractive alternative technique for cell patterning; it is rapid, simple and inexpensive, and the use of 
electrodes to form the shape of the cell aggregate provides versatility when patterning.  
In this paper we use an on-chip, DEP-dot electrode15,28 device as a robust, high throughput, reproducible 
technique of cell aggregation, and investigate the effects of 3D encapsulation on drug effectiveness for 
suspension and adherent cell lines. By comparing the effects of pharmacological interventions on both 
encapsulated 3D cell clusters against both suspension cells and adherent cells grown in their 2D 
environment (suspension or monolayer), we suggest that 3D aggregates of adherent cells show a 
substantially different drug response to cells grown in monolayer, which increases as the IC50 is 
approached, whilst monodisperse suspension cells exhibited similar drug response to those in clusters. To 
explore the differences found in these 2D versus 3D models further, a mathematical model of the system 
for each agent is described; this suggests that changes to drug response are due to inherent changes in 
adherent cells’ response from the 2D to 3D state.  The efficacy of the dot system is also analysed using a 
range of gels including collagen and PuraMatrix, which enables dissociation of the cell aggregates post 3D 
encapsulation; we then use DEP to analyse these encapsulated cells and examine differences in the 
electrophysiological properties of 2D versus dissociated 3D cultured cells.  Differences within the 
membrane properties of the adherent cell type suggest this parameter plays an important role in the 
differences found in the 3D drug response.  
 
Results and Discussion 
1. DEP Dots Demonstrate Robust, Repeatable Aggregation  
Dot electrodes (Figure 1) use negative (repulsive) DEP to contain the cells, by repelling them from the 
edges of circular patterns in the electrode and forcing them into aggregates15. Negative DEP occurs at 
specific frequency ranges, determined by the electrical properties of cells and medium. Optimal 
frequencies were established for each cell type used in the formation of aggregates using a DEPtech 3DEP 
reader (Labtech, Heathfield, UK) as described previously15,22,31.  This approach allowed for cell specific 
aggregation protocols and control of construct size and geometry.  
In order to assess the repeatability (n=100) of aggregate formation in the polyethylene glycol diacrylate 
(PEG-DA) system, aggregate size and cell number were measured for different cell types with different 
properties and diameters, and dot radii between 100-150µm.  Examples of these aggregates are shown 
in Figure 2.   The number of cells per aggregate were measured, showing no significant difference (p> 0.5) 
to their respective means, for all cell types. When aggregate size was compared to the electrode size used 
for aggregation, all cell lines demonstrated similar (p>0.1) aggregate size to dot size ratios (Table 1) with 
aggregates covering just under half of the dot diameter. Since the cell lines used were of similar radii (~ 
10 µm), and resulted in similar aggregate size, this demonstrates that the platform can reliably produce 
aggregates of uniform size.  Interestingly, though the aggregates were of similar relative size, as were the 
cells, the number of cells per aggregate varied, suggesting that changes in cell morphology allowed for 
significantly different packing densities.  
We also established the UV exposure during cross-linking did not negatively affect cell viability by 
monitoring viability with Trypan Blue (as described in Abdallat et al15).  There was no significant difference 
(p > 0.1 ) in viability values, with viabilities recorded in ranges between 92 - 100% for HeLa cells and 94 - 
97% for yeast cells when comparing 2D cell culture methods and cells in 3D aggregates. 
 
 
 
2. DEP-Dots can form aggregates in multiple gelling agents 
Since UV light and the photo-initiator 2,2-dimethoxy-2-phenylacetophenone (DMPA) can be 
hazardous to certain cells, it is beneficial for a 3D cell construction technique to be sufficiently 
flexible to allow the use of alternative gelling agents which are activated by different means; 
similarly, a user may wish to form a gel that (unlike PEG-DA) can be subsequently digested to allow 
recovery of the aggregated cells.   To this end we investigated multiple approaches to gel 
formation using the DEP-Dots. 
 
First, in order to avoid the use of UV exposure we investigated a more biocompatible system using 
PEG-DA and the blue light initiators triethanolamine (TEA) and eosin-Y27 (Figure 3A). Cells were 
observed to form patterns similar to those formed using the UV initiator, as described in the 
previous section.  However, the blue light initiator required a longer curing time (over ten minutes 
under blue light). Aggregate relative size and cell number stayed consistent with our previous PEG-
DA experiments. 
 
Second, we investigated gels with different functional characteristics.  A distinct disadvantage of 
these PEG-based systems is that once cells are encapsulated, they remain in the gel permanently. 
This does not allow for post treatment analysis of the individual cells, or layers of these cells. One 
particularly useful tool would be to characterize changes in the cells pre- and post-encapsulation, 
for example to allow analysis of cell behaviour using flow cytometry.  We have previously shown 
these electrophysiological properties can predict drug IC5022, thus if cells could be obtained post-
encapsulation we could perhaps conduct a similar comparison.  
 
To this end, other hydrogel options were then investigated for aggregate dissociation.   Collagen 
hydrogels (Figure 3B) are a widely used method for scaffolding and tissue engineering.  However, 
this is a challenging gel system for use in DEP; due to the composition, the solution is highly 
conductive and the larger weight volumes necessary for a durable gel (for complete removal from 
the chip) increase the viscosity, rendering movement by DEP force difficult. We were able to 
minimize these effects within the dot array at sufficiently low gel content, and determined 6.75 
w/v% with a solution conductivity of 875 mS/m achieved adequate negative DEP response, and 
produced a sufficiently strong gel to be peeled from the chip intact. This gel system was 
temperature cured, so samples were kept warmed to 40 °C, aggregated with DEP, and then placed 
in an incubator set to 20 °C for ten minutes. These remained intact, and the cells remained viable 
for at least one week after gel formation.  
 
PuraMatrix (Figure 3C) was also investigated with concentrations of 25% yielding adequate 
durability of the gel. PuraMatrix self-assembles when exposed to physiological levels of salt (such 
as culture media) into nanofibers on a scale similar to the extracellular matrix. Like collagen, 
PuraMatrix can be dissociated, and whilst fibre density and pore size can be more tightly 
controlled (a crucial criteria for drug/molecular studies), at 25% concentration necessary for 
encapsulation, it is the most expensive option. 
 3. Drug Efficacy of 2D versus 3D Varies in Suspension and Adherent Cells  
Since the primary function of most 3D cell cultures is in the assessment of the efficacy of new 
pharmaceutical interventions, it is important to understand how, and why, this response differs from a 
2D culture.  To this end, two drugs, in wide clinical use, were investigated to benchmark their response in 
3D against their 2D model.  
Vinblastine is a chemo-therapeutic agent that interferes with the cell’s ability to undergo mitosis by 
binding to tubulin and inhibiting microtubule production causing mitotic arrest and, ultimately, cell 
death32. Amphotericin B (AmB) is an anti-fungal agent that acts by stopping the production of ergosterol 
which causes channels to open in the fungal cell membrane, which compromises the cell and ultimately 
leads again to cell death33. Both Vinblastine and Amphotericin B are small molecule drugs of similar 
molecular weight (909.05 Da and 924.079 Da, respectively) and as such can be assumed to diffuse similarly 
through hydrogels.  
First, the effect of vinblastine on the survival of patterned and encapsulated HeLa aggregates was 
investigated (Figure 4A & 4B). Statistical analysis indicated that the control sample for monolayer and for 
aggregates had no significant difference in their cell viability. With regards to viability of exposed cells to 
the drug concentration of 11μM, monolayer viability dropped by an average of 62% after 3 h of drug 
incubation, compared to an average of 13% for aggregates.  
When viability was measured at 48 h post treatment, it was observed to have dropped further, reaching 
a mean viability of 18% in 2D monolayer and 71% in 3D cell aggregates. Control samples for both 2D and 
3D remained above 90% viable. The mean viability for the experiments showed that the viability for 2D 
monolayer dropped immediately after drug incubation, and the drug had a prolonged effect which 
decreased viability further 48 h post drug removal. The 3D aggregates did not experience the same 
immediate drug effect, as viability only decreased to 78%; however, they did continue to decrease at 48 
h post treatment (Figure 4C). 
This was then compared with the result of a second test; the action of AmB on yeast cells used to form 
similar cell aggregates. Since yeast cells are unicellular organisms which grow in suspension (in their 
natural shape) in isolation and do not normally interact with adjacent cells, they provide a suitable control 
to assess whether the process of cell resistance in clusters is due to simple blocking of cells against 
diffusional processes by cell packing, or a more complex process whereby cell morphology and inter-cell 
communication allows the cells to better adapt to the presence of the toxin. Control samples for the 2D 
(cells suspended in YPD broth) and 3D aggregates demonstrated viability above 96%. These were also 
used to establish estimated growth curves of the healthy yeast over a 48 h period (due the more rapid 
doubling time compared to human cell lines). The treated cells started demonstrating significant viability 
decrease (p<0.01) for the 2D treatment at 16 µg/ml reaching a viability below 50% at 160 µg/ml. The 3D 
treated cells followed a similar viability curve remaining higher than the 2D treated cells, though only 
significantly so (p<0.001) for the 160 µg/ml treatment. Again, a 48 h post-treatment follow-up was 
conducted to examine the long-term effects of the drug treatment in 2D and 3D culture (Figure 4D). 
Control samples for 2D demonstrated an 82% viability whilst the 3D samples were still 96% viable. With 
each increase in AmB viability decreased with the 160 µg/ml treated cells exhibiting viability of 7% and 
29% for 2D and 3D respectively.  
The effectiveness of standard drug treatment of adherent cells (which naturally interact with 
surrounding cells in vivo) was shown to differ with that in yeast cells (which only act as 
independent unicellular organisms) when grown in similar conditions. The results obtained from 
HeLa 2D HeLa monolayers and 3D aggregates were found to be significantly different (p<0.05) at 
all drug concentrations. However, the difference in drug effectiveness in suspension  versus 3D 
culture in yeast only showed a 16% change between the different culture conditions.  Taken 
together, this study confirms that both suspension and adherent cells do respond to drug treatments 
differently in a 3D environment when compared to their 2D counterpart, as has been previously 
demonstrated 34. However, this also raises questions about the reason for this change in behaviour. 
In order to explore this further, we developed a model of molecule diffusion through the aggregates.  The 
drug concentrations within the entire DEP dot array can be calculated from the diffusion equation20. Given 
that the lateral extent of the array (5 mm) is significantly larger than its thickness (300 µm) it is sufficient 
to consider the transport of the drug through the thickness alone so that we solve: 
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where 𝐷𝑔 is the diffusion coeffcient specific to the drug and gel. The boundary and initial conditions are 
𝑐 = 𝑐𝑚𝑎𝑥 at 𝑧 = 0, 𝐿 and 𝑐 = 0 at 𝑡 = 0, where 𝑐𝑚𝑎𝑥 is the concentration of the medium in which the 
array is submerged and 𝐿 is the gel thickness, which we have taken as 300 µm throughout. The solution 
of Eq. 2 with these initial and boundary conditions may be obtained by the method of separation of 
variables as: 
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A range of diffusivities have been reported in the literature35-37, and choosing the value corresponding to 
the slowest diffusion (Dg= 3.3x10-10 m2 s-1 27), we plot in Figure 4E the concentration in the middle of the 
DEP array. We find that the drug saturates the prepared samples within minutes. This is significantly 
shorter than the experimental timescales, so that the gels may be considered to be at a uniform 
concentration equal to the applied concentration cmax, so that diffusion through the gel is not a limiting 
factor. 
Turning now to a model of an individual aggregates (Figure 4F) within each dot, we can consider each dot 
as a cylinder of gel with a dome-like cell aggregate at its base. The diameter of the aggregate has been 
measured as 0.46d (Table 1); in these simulations we used d=300 µm (the largest value measured) and 
𝐿=300 µm. 
Within each dot we solved the full three-dimensional diffusion equation:  
 
𝜕𝑐
𝜕𝑡
= ⁡𝐷∇2𝑐 − 𝑓(𝑐) (3) 
where 𝑓(𝑐) is a term accounting for removal of drug from the system. Within the inert encapsulating gel, 
we take 𝑓(𝑐) = 0 and the diffusion constant  𝐷 = 𝐷𝑔. Within the aggregates, we allow for removal of the 
drug from the system by cellular processes by incorporating a positive 𝑓(𝑐) and take 𝐷 = 𝐷𝑐 < 𝐷𝑔 as a 
modified diffusion coefficient for the cellular aggregate38. The boundary conditions are as before that 𝑐 =
𝑐𝑚𝑎𝑥 at the top and bottom surfaces 𝑧 = 0, 𝐿, complemented by a no-flux condition at the outer edge of 
the cylinder so that drug may not leave the dot through the sides. Continuity of concentration at the 
interface between gel and aggregate is always assumed. The initial condition is that 𝑐 = 0 at 𝑡 = 0. 
Whilst different drug responses are often observed in 3D aggregates when compared to cells in 2D culture, 
it is a matter of conjecture as to whether these are due to the packed outer cells reducing the diffusion to 
the inner cells, or due to changes in the drug response of the individual cells when grown in 3D. Our model 
suggests that without any modification to drug transport within the cellular aggregates, the inner cells 
would be rapidly exposed to any applied small molecule drug.  Indeed, our model suggests that, in the 
absence of an additional protection mechanism such as cellular uptake (i.e. if (𝑐) = 0 ), uniform high 
concentration is achieved in time ~O(r2/Dc). For the small aggregates studied here, this is relatively short; 
simulations based on the reported diffusivities for e.g. Vinblastine in cellular aggregates30 show that over 
90% of the cells experience 𝑐𝑚𝑎𝑥 within ~7 minutes.  Even considering the reduced effective diffusivities 
that have been reported in three-dimensional tissues35-37,39 for a range of substances including vinblastine, 
oxygen, sodium fluorescein and dextrans, this is insufficient to prevent the chemicals reaching the center 
of the aggregate within a timescale short in comparison with the study length. 
In order to account for the observed reduced effectiveness of Vinblastine in 3D we incorporated the loss 
term 𝑓(𝑐) in Eq. 3 when solving the diffusion equation in the aggregate. Many different functional forms 
for 𝑓(𝑐) are commonly used including constant40, linear41 and hyperbolic42. However, the data for HeLa 
response to vinblastine in Figure 4C shows a relatively weak dependence on 𝑐𝑚𝑎𝑥, suggesting a good first-
order approximation is 𝑓(𝑐) = −𝑘𝑐; in this case the applied concentration may be scaled out of the 
solution by setting 𝑐 = 𝑐/𝑐𝑚𝑎𝑥.  
This model provided a solution which demonstrated limited drug penetration to the centre of the 
aggregate, with the depth of drug penetration determined by the diffusive length scale parameter 
(=(Dc/k)). We solved Eq. 3 (aggregate) to arrive at a steady-state solution using COMSOL (COMSOL 
Multiphysics v.5.2, Stockholm, Sweden). The results for vinblastine applied to HeLa aggregates (with 𝐷𝑔 =
3.3⁡𝑥⁡10−10 m2s-1, 𝐷𝑐 = 1.9⁡𝑥⁡10
−12 m2s-1, and 𝑘 = 0.01 s-1) are shown in Figure 4G; this shows a region 
of low drug concentration in the centre of the aggregate which is effectively ‘protected’ by the outer layer 
of cells removing drug from the system by a combination of factors. Solving the full time-dependent 
model, we found that this steady-state solution is effectively achieved within five minutes. However, from 
the model alone it is impossible to distinguish between the protective effects of reducing Dc or increasing 
cellular absorption k as they only appear in ratio in the effective diffusive length scale. 
Since the tightly-packed yeast cells would present similar simple inhibitory barriers to drug 
diffusion in 3D to those seeing in the HeLa model, we propose that this suggests that diffusion in 
3D is not the primary reason for the change in HeLa behaviour, and that (as in the situation 
described elsewhere38) the primary reason for differences in cell behaviour is due indeed to cell-
cell interaction and cytoplasmic changes that allow the cell to better mitigate the action of the 
drug in this case. In Figure 5 HeLa cells are shown in their 2D monolayer state (Figure 5A) in which 
cell attachment and actin activity can be observed, in the 3D aggregate similar cell attachment can 
be seen when comparing treated (non-viable) cells (Figure 5B) to healthy cells (Figure 5C) . 
Compared to constructing aggregates formed spontaneously or by culturing them on treated 
surfaces, the hydrogel system represents a structure more like the original tissue in terms of 
having a polymer surrounding cells, which serves as a barrier that can represent blood (growth 
medium with dissolved drug) and extracellular matrix (hydrogel). Clearly this is significant in the 
development of new pharmaceuticals, particularly in the use of the IC50 model, where the clinical 
relevance of cell toxicity in vivo based on cell viability in vitro is clearly to be called into question. 
4. Measuring electrophysiological changes post 3D encapsulation 
Previous work23 suggested that cells grown in 3D differed in their electrophysiology from those 
grown in 2D culture.  In order to conduct a more rigorous study into the effect of DEP-based 3D 
cell culture on cells, we investigated the properties of yeast, K562, and HeLa cells after culture. 
Briefly, trypsin was added to both the 2D and 3D cell cultures for the same amount of time (this 
varied by a few minutes per sample, but was kept constant between the 2D and 3D replicates). 
Once the gels were dissociated, cells were resuspended in 10mSm -1 DEP buffer, sonicated and 
analysed in the 3DEP reader (Labtech, Heathfield, UK) 22,29,31. Cellular properties of cells grown in 
2D for 24 h and 48 h were compared to those grown in 3D for 24 h and 48 h.  The results are 
summarised in Figure 6. 
 
Analysis of the dielectric properties of these cells revealed significant (p<0.0001) changes in the 
membrane capacitance for HeLa cells post 3D encapsulation compared to the 2D model (Figure 
6C) whereas for both suspension cell types, this parameter did not change significantly. 
Membrane conductance for both the yeast and K562 demonstrated a significant change (p<0.001) 
due to 3D encapsulation (Figure 6A & 6B) however for yeast this effect was only observed at 24 h. 
The decrease in membrane conductance on the K562 cell line, with no changes in other 
parameters observed, could be an early indicator of changes to cell functionality2.  In common 
with previous studies of cells following 3D culture24, variation in the membrane capacitance of the 
adherent HeLa cell types was the most significant change in electrophysiology post 3D 
encapsulation; there were no similar changes observed in the two suspension cell lines. Since no 
changes to cell radius were observed (n=100 cells measured with p>0.05 between the two groups) 
the change observed in the membrane capacitance of HeLa cells from 2D to 3D suggests changes 
to the membrane morphology have occurred.   
 
The mean difference between each of the properties measured was investigated to determine 
whether changes in electrophysiology between 2D and 3D were significantly different between 
cell types (Figure 7). HeLa cells were found to differ between 2D and 3D in ways which differed 
significantly from the other two cell types (p < 0.0001 in most cases).  The change in both 
membrane capacitance and membrane conductivity from 2D to 3D between K562 and HeLa cells 
was consistently significant (p<0.0001 in most cases, p<0.01 in Figure 7A); interestingly, the K562 
cells differed in properties in a manner similar to yeast cells (another suspension cell), rather than 
HeLa (another mammalian cell).  Also of note is that whilst differences are still observed between 
2D and 3D cells after 48 hours, these differences are smaller than those observed after 24h. It is 
possible that changes may be due to trypsinisation, though a study43 of DEP response of cells to 
various detachment methods suggested that this does not have a significant effect on K562 cells.  
 
Could changes in membrane capacitance be responsible for the differences found in the 2D versus 
3D drug response of HeLa cells? It is notable that the morphology change only occurs in adherent 
cells, and may reflect an integration of the cell layer – possibly through gap junctions – that might 
allow the cells to mitigate the effects of drugs.  However, this would need to be investigated 
further.   
 
This also demonstrates the flexibility of gel culture systems for applications that involve 
dissociation of the gel and aggregate for further analysis, such as analysing drug diffusion through 
layers of aggregate to study the necrotic core of a tumour model. 
 
Conclusions 
The use of dielectrophoresis in the development of 3D cell aggregation for the field of tissue 
engineering was successfully demonstrated and optimised. This technique proved to be a robust, 
high-throughput, method of on-chip cell aggregation.   The primary application of this technique 
for the use in toxicological assays was established and its utility for analysing cells post 3D 
encapsulation was demonstrated. There was a marked difference in the viability values in 3D 
cultures compared to 2D cell cultures, with adherent cell types demonstrating a greater difference 
in the 2D versus 3D environments than suspension cells. Analysis of the electrophysiological 
properties of cells cultured in 2D and 3D environments revealed changes to the membrane 
capacitance of the adherent HeLa cell line after 3D encapsulation was significantly different to 
both the yeast and K562 suspension cell types.    This eludes to membrane properties, perhaps 
morphology or cell-cell interactions having a critical role in 3D cell drug resistance. Further, other 
gel systems in which aggregates can be dissociated or co-cultured demonstrated the possibility of 
this DEP based technique to address these critical future steps in tissue engineering.  
 
  
Methods 
DOT Array Fabrication 
The microelectrode arrangement was developed based on the ‘DEP-dot’ system28; a photolithographic 
process 15,28 was used to fabricate gold electrodes (EPSRC Centre for III-V Technologies, UK) of 200nm 
thickness and photo-polymer resin (Poly-Diam, UK) gaskets of 300 µm thickness (Figure 1). After thorough 
cleaning of the electrodes, the gasket material was temporarily adhered between the top indium tin oxide 
(ITO) electrode (Delta Technologies, USA) and patterned array. These were left overnight prior to 
aggregation. 
Continuous Phase Matrix (CPM) 
Pre-polymer PEG-DA (MW 575) was mixed with prepared DEP medium (described for each cell type 
below) at 15% PEG-DA. The photo-initiator 2,2-dimethoxy-2- phenylacetophenone (DMPA) was dissolved 
in catalyst 1-vinyl-2-pyrrolidone (NVP) at 100 mg/mL. Once cells were resuspended in the pre-polymer 
DEP solution, DMPA was added to 1ml of cell suspensions at 0.01% v/v.  
We initially investigated the most commonly used blue-light photo-initiators found in the literature; 
camphorquinone (CQ), eosin-y (E-Y) and triethanolamine (TEA)44 (Sigma-Aldrich). Following protocols for 
optimal cell viability 30,45  initial investigation of these initiators in the DOT electrode system revealed E-Y 
and TEA cured PEG in approximately 6 minutes, CQ and TEA cured in approximately 10 minutes, and CQ 
alone did not cure within 10 minutes. Thus the E-Y and TEA combination was used for all further testing. 
These were prepared in 15% PEG at 0.1mM and 0.2% respectively.  
Powdered gelatin (from porcine skin, type A, 300 bloom) was dissolved in a prepared buffer solution at 
6.75%w/v. Conductivities of these were about 875 mSm-1 at 40°C. Cell suspensions in the gelatin were 
kept in a water bath at 40°C and periodically sonicated to prevent temperature dependent gelation. 
PuraMatrix™ was investigated at 25% concentration of the precursor solution in the prepared buffer 
solution with conductivity of 100 mSm-1.  
Yeast maintenance and preparation 
Baker’s yeast (Tesco, UK) was grown in yeast extract peptone dextrose (YPD) broth (50 g/L) (Sigma Adrich, 
UK) at 4 ℃, collected using a sterile loupe and then grown in YPD broth for 17 hr at 37 ℃. Cells were 
washed twice in 1 ml D-mannitol (~280 mmol L-1) (Sigma Aldrich,UK) with PBS (Sigma Aldrich,UK) added 
to achieve a conductivity of 10 mSm-1.  Cell concentration was then adjusted to a final concentration of 
2x107 cells ml-1 and resuspended in prepared CPM.  
Cell Line Maintenance and Preparation 
Human K562 cells were cultured in RPMI-1640 media at 37°C, supplemented with 10% heat-inactivated 
FBS (Biosera, UK), 1% L-glutamine and 1% penicillin–streptomycin. Cells were washed in low conductivity 
DEP buffer medium containing 8.5% sucrose and 0.3% dextrose and resuspended in CPM at a final 
concentration of 106 cells ml-1. HeLa cells were cultured in MEM with Earle’s salts and non-essential amino 
acids (Biosera, UK) supplemented with 10% heat-inactivated FBS (Sigma-Aldrich, UK), 1% L-glutamine and 
1% penicillin–streptomycin (Sigma Aldrich, UK). At about 80% confluency, cells were trypsinized and 
washed twice in DEP buffer medium and resuspended in CPM at a final concentration of 106 cells ml-1. HL-
1 cells were cultured in Claycomb media supplemented with 10% heat-inactivated FBS, 1% penicillin-
streptomycin, 1% L-glutamine and Norepinephrine (0.1mM) (Biosera, UK). The cells were trypsinised at 
100% confluence and washed twice in DEP buffer medium before resuspending in CPM at a final 
concentration of 106 cells ml-1. Viability of cell suspensions was confirmed on control samples prior to 
experiment using a LIVE/DEAD Staining Kit (Sigma Aldrich, UK). Further viability was monitored with 
trypan blue (Sigma Aldrich, UK). 
DEP Aggregation 
For optimal negative DEP patterning, DEP crossover frequencies were established through analysis by 
DEPtech 3DEP reader 22,29,31 (Labtech, Heathfield, UK) of each cell line within the CPM.  DEP patterning 
was conducted at 10 Vpp and 2-10 kHz (depending on cell crossover frequency). Cell aggregation and 
encapsulation was carried out over 4 min (3.5 min patterning and 30 s UV exposure using the UV 
irradiating DEP box described elsewhere10). The resultant hydrogel was removed and placed in a 12 well 
plate with fresh culture medium. Control aggregates were assessed for viability either by trypan blue 
(Sigma Aldrich, UK) staining or through the LIVE/DEAD Viability assay. The hydrogels were incubated for 
up to 5 days depending on the purpose of the particular study.  
Hydrogel dissociation for DEP experimental 
Cells were removed from their 3D model formed by the DEP dot electrode using PuraMatrix gel system 
for DEP experiments. This was achieved by washing the hydrogel encapsulated cells with PBS (Sigma 
Aldrich,UK), then pipetting tryspin (Sigma Aldrich,UK) into the well enough to cover the hydrogel layer. 
Simultaneously, trypsin was added to a culture flask of 2D cultured cells washed with PBS. Time was 
monitored to ensure 3D and 2D tryspin exposure remained consistent. When necessary, sonication of the 
aggregates was performed to break apart clumps of cells. Once cells were dissociated, cells were washed 
in 5 mL of their respective DEP buffer and prepared at a concentration of 106 cells ml-1 for DEP 
characterization.  
Drug Treatment and Measurement 
Yeast treatment.  Amphotericin B (AmB), a common anti-fungal drug, was prepared by dissolving 5 mg of 
AmB powder in 1 ml of DMSO and then mixed in YPD broth for a final concentration of 160.0 µg/ml. Serial 
dilutions were then used to make up concentrations ranging from 5-160 µg/ml which, when applied in a 
10:1 dilution gave applied concentrations ranging from 0.5-16 µg/ml. A 12-well plate was used to conduct 
drug tests on both 2D cell suspensions and 3D aggregates. Cells encapsulated in hydrogels followed the 
same drug treatment regime as those in YPD solution. 
HeLa Treatment.  Vinblastine sulphate salt powder ≥96% (Sigma Aldrich,UK), a common anti-cancer drug, 
was dissolved in sterile filtered distilled water (10mg/ml) to make up a stock solution of 11mM. For each 
experiment 100 µL of stock solution was diluted in complete HeLa growth medium to make up four 
different concentrations of 11μM, 1.1μM, 0.1μM and 27.5nM, selected based on previous work46,47 and 
henceforth referred to as concentrations 1 to 4 respectively. Hydrogels were kept in well plates containing 
complete growth medium solution for 5 days (the time at which cells were observed to begin adhering to 
one another). The drug was administered and left to incubate for 3 h. Viability was tested using Trypan 
blue prior to and after treatment.  
For 2D monolayer experiments, six T75 flasks were used to seed HeLa cells taken from the same source 
used to make each set of hydrogels. In order to use the same cell sample through the treatment no 
staining was administered to assess viability. Instead, for each drug concentration cell counts were taken 
of adherent cells on defined areas of the flask prior to drug treatment. Cells were treated and then 
incubated for 3 h. The same defined area of the flask was then counted for adherent cells. Following this, 
both monolayers and hydrogels were incubated for 48 h to examine any effects of post vinblastine 
treatment.  
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Tables 
Table 1 
Cell Type Frequency (kHz) Cell Radius (µm) Cells per Aggregate Aggregate Diameter/Dot Diameter 
Yeast 10 3.5 ± 0.8 300 ± 26 0.465 ± 0.04 
HeLa 5 10.3 ± 1.1 32 ± 5 0.462 ± 0.03 
K562 7 10.4 ± 1.5 54 ± 8 0.468 ± 0.03 
HL-1 2 10.2 ± 1.5 75 ± 6 0.456 ± 0.02 
 
Table 1: Aggregate characterisation (n=100) for the various cell types. 
  
Figures 
Figure 1 
 
 
Figure 1: Schematic of the DEP dot array. The removable gasket connects the ITO ground electrode to 
the gold array and also serves as the reservoir in which the CPM and cell mixture is contained. The 
height of the gasket is approximately 280 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 
 
Figure 2: DEP DOT Electrode repeatability across cell types. The following cell types were encapsulated 
in PEG-DA A. yeast, B. HL-1 C. K562, and D. HeLa. The resultant peeled gel is shown (E) with a thickness 
of approximately 280 µm and width of approximately 5mm. The peeled gels, like that shown, were 
placed in well plates for cell culture and subsequent drug treatment. 
  
Figure 3 
 
 
Figure 3: The DEP DOT Electrode system is consistent in cell aggregation using various gel systems. A. 
K562 cells in PEG-DA cross linked under blue light with initiators TEA and eosin-Y. B. Yeast cells in 
6.75% w/v collagen, and C. Yeast cells in 25% PuraMatrix. 
  
Figure 4 
 
Figure   4: (A) HeLa cells aggregated prior to drug treatment and (B) viability of HeLa cells in aggregates 
assessed with live/dead assay. (C) Average HeLa response curves for monolayers and aggregates 48 h 
post-treatment with vinblastine. (D) Average Yeast response curves for monolayers and aggregates 48 
h post-treatment with Amphotericin B  (E) Drug concentration of drug (Vinblastine/AmB) in the 
middle of gel layer as a fraction of the applied concentration cmax, calculated from Eq. 5 with Dg= 
3.3x10-10 m2 s-1 and L=300 µm. (F) Geometry of a single DEP array dot with cellular aggregate, L = 
300µm and d = 300µm and the aggregate is modelled as a half sphere of diameter 0.46d. (G) Drug 
concentration of drug vinblastine in DEP gels as fraction of applied concentration cmax in a section 
through the centre of the cellular aggregate. Drug concentrations obtained by solving Eq. 3 in i) a 
cellular aggregate region with Dc=1.9 x 10-12 m2 s-1, k=0.01 s-1 and ii) a gel region with Dg= 3.3x10-10 
m2 s-1 and  k=0  s-1. 
Figure 5 
 
 
Figure 5: A. HeLa cells grown in monolayer on a standard culture flask, B. HeLa cells aggregated and 48 
h post treated with 11µM of Vinblastine and C. HeLa cells aggregated and cultured with no treatment. 
From B it is visible that the treated cells lack the cell-cell connections shown in C of the untreated 
cells.   
  
Figure 6 
 
 
Figure 6: The three electrohpysiological parameters determined through the single-shell model 
analysis in 3DEP. Membrane capacitance, Membrane conductance, and cytoplasmic conductivity were 
determined for yeast (A), K562 (B) and HeLa (C) cells grown in their appropriate 2D models 
(suspension or monolayer on a flask surface) and cells removed from their 3D model formed by the 
DEP dot electrode using PuraMatrix gel system. Values on the graphs are given as the mean (n=5) 
calculated parameter determined by fitting DEP spectra data of the cells to a single shell model ± SEM 
p<0.01. 
  
Figure 7 
 
 
Figure 7: The mean difference between the 2D and 3D cell properties were determined and compared 
across cell types. Values given are the mean differences calculated between the means of 2D and 3D 
(Figure 6) +SEM. 
